European Journal of Preventive Cardiology

FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platform

Retrieved on: 
Thursday, November 2, 2023
Software, Professional Services, Pharmaceutical, Optical, Venture Capital, Technology, Medical Devices, Artificial Intelligence, Cardiology, Biotechnology, Medical Supplies, FDA, Health, Stanford University, Food, Genetics, Mortality, Breakthrough, Disease, Entrepreneurship, Regulation of tobacco by the U.S. Food and Drug Administration, Multimedia, CVD, American Heart, Risk, Hypertension, Health equity, Risk assessment, Pharmacy, Eye, Blood, AI, European Journal of Preventive Cardiology, MSEE, Patient, Emory University School of Medicine, Retina, Clair, Cardiovascular disease, Medical device, Medical imaging, Pharmaceutical industry, Ophthalmology, MD

Toku, Inc., a commercial medical device company specializing in imaging technology and AI, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its patented CLAiR technology.

Key Points: 
  • Toku, Inc., a commercial medical device company specializing in imaging technology and AI, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its patented CLAiR technology.
  • The CLAiR platform, if cleared by the FDA, will be the first medical device in the US market that can provide affordable, point-of-care and non-invasive evaluation for risk of cardiovascular disease (CVD) using fundus retinal images through a routine eye exam.
  • Working with its partners, Toku is aiming to establish the largest network for CVD risk assessment across the US and then globally.
  • View the full release here: https://www.businesswire.com/news/home/20231102799522/en/
    Toku's AI-powered CLAiR technology uses retina scans during regular eye exams to detect cardiovascular risk non-invasively.

Evie Ring Welcomes Cardiologist and Stanford University Associate Professor Dr. Fátima Rodriguez to its Medical Advisory Board

Retrieved on: 
Tuesday, September 12, 2023
Harvard Kennedy School, Stanford University, Section, Cardiovascular disease, Human, Research, Center for Public Leadership, Evie, Associate, Harvard Medical School, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Public health, Cardiology, European Journal of Preventive Cardiology, Coronary artery disease, Health, MPH, Female, Medical device, MD

PLEASANTON, Calif., Sept. 12, 2023 /PRNewswire/ -- After recently announcing the establishment of its Medical Advisory Board, Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of the Evie Ring, today shared Dr. Fátima Rodriguez has joined as its newest member.

Key Points: 
  • Dr. Fátima Rodriguez, MD, MPH is an Associate Professor and Section Chief of Preventive Cardiology at Stanford University, and a practicing noninvasive and preventive cardiologist.
  • Dr. Rodriguez specializes in cardiovascular disease prevention, inherited lipid disorders, and cardiovascular risk assessment in high-risk populations.
  • Dr. Rodriguez earned her medical degree from Harvard Medical School and her MPH from the Harvard School of Public Health as Zuckerman Fellow at the Harvard Kennedy School's Center for Public Leadership.
  • In addition to Dr. Rodriguez, Evie's Medical Advisory Board is comprised of experts from various disciplines, including:

Family Heart Foundation Research Finds High-Risk Americans Who Do Not Maintain Guideline Recommended LDL-C Targets Have 44% Higher Rate of Cardiovascular Events

Retrieved on: 
Tuesday, March 21, 2023
Men, Research, General Health, Philanthropy, Pharmaceutical, Consumer, Foundation, Science, Cardiology, Women, Other Philanthropy, Health, Other Science, University of Texas Southwestern Medical Center, AT, AMCP, University Challenge 2013–14, Policy, Cardiovascular disease, LLT, Patient, Circulatory system, Academy of Managed Care Pharmacy, Diagnosis, European Journal of Preventive Cardiology, Poster, American College, CDT, EXPO, Conference, Pharmaceutical industry, Medicine

“Often that means taking the right statin, sometimes it means taking more than one medication.

Key Points: 
  • “Often that means taking the right statin, sometimes it means taking more than one medication.
  • No matter how a person gets there, this study shows that living in the ’safe zone’ when it comes to LDL-C control means fewer cardiovascular events over time.
  • Despite LDL-C being a major modifiable risk factor for cardiovascular disease, most patients do not achieve guideline thresholds and even fewer maintain those levels even if they do achieve them.
  • Key findings showed:
    The Family Heart Database is comprised of real-world diagnostic, procedural, and prescription data from claims and/or laboratory information in the U.S. from 2012 to 2021.

Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-driven HART CVE Blood Test Highly Accurate for Predicting Major Cardiac Events in Patients with Chronic Kidney Disease

Retrieved on: 
Thursday, November 3, 2022
Cardiology, Technology, Health, General Health, Health Technology, Research, Software, Artificial Intelligence, Hospitals, Science, Clinical Trials, American Heart Association, Public health, Company, Journal, HART, Arrest, Heart, Machine learning, Medicare, International Journal of Cardiology, CVE, AI, Congress, Chronic kidney disease, Principal, Biomarker, Open heart, Clinical Cardiology, Stroke, AUC, Algorithm, Centers for Disease Control and Prevention, Center, Massachusetts General Hospital, European Society of Cardiology, Canadian International Council, CKD, Artificial intelligence, The American Journal of Cardiology, Hospital, Kidney disease, Harvard Medical School, Risk, Cardiovascular disease, American College of Cardiology, AHA, Patient, MD, European Journal of Preventive Cardiology, Medical device, Cardiology, Medicine

Researchers from Massachusetts General Hospital tested 446 CKD patients undergoing coronary or peripheral angiography to predict two-year risk of heart attack, stroke, or cardiovascular death.

Key Points: 
  • Researchers from Massachusetts General Hospital tested 446 CKD patients undergoing coronary or peripheral angiography to predict two-year risk of heart attack, stroke, or cardiovascular death.
  • This accuracy across the different stages is important given a sharp increase in cardiovascular event risk as patients progressively decline in kidney function.
  • This HART CVE application is valuable for both hospitalized and outpatient chronic kidney patients.
  • In addition to the HART CVE test for risk of major cardiac events, Prevencio offers a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries.

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Retrieved on: 
Monday, August 22, 2022
Cardiovascular disease, Cardiology, COVID-19, Conditional sentence, Non-alcoholic fatty liver disease, Safety, Cell, Legislation, Breakthrough therapy, Risk, HHF, Moderate, Disease, US Foods, FS, Virus, Food, BD2, BET, TSX, GLOBE, Intention, Â, Cirrhosis, Company, FDA, Bromodomain, American Journal, News, Type 2 diabetes, MACE, SEDAR, Industry, Human body, European Journal of Preventive Cardiology, Acute coronary syndrome, End organ damage, Nature, Pharmaceutical industry, Dietary supplement, Medical device, Apabetalone, Patient

The article presents a post-hoc analysis of BETonMACE data, which demonstrates apabetalone treatment improves cardiac outcomes and liver fibrosis scores in patients with moderate-to-high likelihood of advanced liver fibrosis.

Key Points: 
  • The article presents a post-hoc analysis of BETonMACE data, which demonstrates apabetalone treatment improves cardiac outcomes and liver fibrosis scores in patients with moderate-to-high likelihood of advanced liver fibrosis.
  • These promising findings make the case for a larger study of non-alcoholic fatty liver disease patients to better understand the scope of apabetalones benefit.
  • It is a BD2 (bromodomain) selective BET (bromodomain andextra-terminal) inhibitorthat works in preventing and treating disease progression byregulating the expression of disease-causing genes.
  • Data from BETonMACE showed apabetalone can potentially prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.

Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-driven HART CVE Blood Test Highly Accurate in Patients with Diabetes for Predicting Heart Attack, Stroke, and Cardiac Death Risk

Retrieved on: 
Tuesday, April 12, 2022
Biotechnology, Diabetes, Health, Cardiology, Patient, European Journal of Preventive Cardiology, Cardiovascular disease, American Diabetes Association, AUC, Biomarker, Population, Stroke, CVE, MD, Algorithm, Death, Hospital, The American Journal of Cardiology, Heart, Health, Company, Principal, American College of Cardiology, Artificial intelligence, Journal, AI, Machine learning, American College, Clinical Cardiology, Massachusetts General Hospital, European Society of Cardiology, Diabetes, Â, Harvard Medical School, Arrest, Risk, ACC, HART, Congress, American Heart Association, Medical device, Pharmaceutical industry, Medicine, Cardiology

Cardiologists from Massachusetts General Hospital tested 450 subjects to predict one-year risk of heart attack, stroke, or cardiovascular death in patients with diabetes.

Key Points: 
  • Cardiologists from Massachusetts General Hospital tested 450 subjects to predict one-year risk of heart attack, stroke, or cardiovascular death in patients with diabetes.
  • In addition to the HART CVE test for one-year risk of a major cardiac event, Prevencio offers a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries.
  • HART CADhs was shown to be more accurate (86% AUC accuracy) than standard-of-care stress tests (52% AUC accuracy).
  • Patients with diabetes have twice the rate of cardiovascular disease as compared to patients without diabetes.

AHN Chief Nurse Executive Claire Zangerle Named Fellow, American Academy of Nursing

Retrieved on: 
Tuesday, August 24, 2021
Network, Master of Business Administration, American Academy of Nursing, Associate degree, Growth, VNA, Health policy, Quality, Visiting nurse association, Trauma, Academy, Allegheny Health Network, Policy, Texas A&M University, Queen's Nursing Institute, Research, Fellows, American Academy, Kent State University, RN, Health, Texas Christian University, Memorial Hermann–Texas Medical Center, AHN, Hospital, Houston Baptist University, Public health, Cleveland, Lake Erie College, National Association Medical Staff Services, European Journal of Preventive Cardiology, CEO, Conference, Health equity, Business administration, COVID-19, Workforce, Medicine, Pharmaceutical industry

PITTSBURGH, Aug. 24, 2021 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) Chief Nurse Executive Claire Zangerle DPN, RN, has been selected as a Fellow of the American Academy of Nursing, a recognition granted to nursing's most accomplished leaders in policy, research, practice, administration and academia.

Key Points: 
  • PITTSBURGH, Aug. 24, 2021 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) Chief Nurse Executive Claire Zangerle DPN, RN, has been selected as a Fellow of the American Academy of Nursing, a recognition granted to nursing's most accomplished leaders in policy, research, practice, administration and academia.
  • "Claire Zangerle is an exceptional, dynamic, healthcare executive and nurse-leader who has been instrumental to the growth and success of our organization, and we are thrilled to see her recognized by the American Academy of Nursing," said AHN President and CEO Cynthia Hundorfean.
  • At AHN, Dr. Zangerle serves as the inaugural chief nurse executive at the network, building the infrastructure that supports the continuum of nursing practice.
  • The American Academy of Nursing serves the public by advancing health policy and practice through the generation, synthesis, and dissemination of nursing knowledge.